Wockhardt Yönetim
Yönetim kriter kontrolleri 4/4
Wockhardt's CEO is Murtaza Khorakiwala, appointed in Apr 2009, has a tenure of 15.58 years. total yearly compensation is ₹21.20M, comprised of 95.3% salary and 4.7% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth ₹367.64M. The average tenure of the management team and the board of directors is 13.2 years and 7.5 years respectively.
Anahtar bilgiler
Murtaza Khorakiwala
İcra Kurulu Başkanı
₹21.2m
Toplam tazminat
| CEO maaş yüzdesi | 95.3% |
| CEO görev süresi | 15.6yrs |
| CEO sahipliği | 0.2% |
| Yönetim ortalama görev süresi | 13.2yrs |
| Yönetim Kurulu ortalama görev süresi | 7.5yrs |
Son yönetim güncellemeleri
Recent updates
Wockhardt Limited's (NSE:WOCKPHARMA) Shares Climb 29% But Its Business Is Yet to Catch Up
Nov 02
What Wockhardt Limited's (NSE:WOCKPHARMA) 27% Share Price Gain Is Not Telling You
Aug 20Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jul 27Wockhardt Limited (NSE:WOCKPHARMA) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Jun 30Shareholders Will Probably Not Have Any Issues With Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation
Jun 22Subdued Growth No Barrier To Wockhardt Limited (NSE:WOCKPHARMA) With Shares Advancing 29%
Feb 21There's Reason For Concern Over Wockhardt Limited's (NSE:WOCKPHARMA) Massive 28% Price Jump
Dec 19There's No Escaping Wockhardt Limited's (NSE:WOCKPHARMA) Muted Revenues
Oct 14Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Jun 23Estimating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Feb 18Wockhardt (NSE:WOCKPHARMA) Is Making Moderate Use Of Debt
Jan 04Shareholders Will Probably Hold Off On Increasing Wockhardt Limited's (NSE:WOCKPHARMA) CEO Compensation For The Time Being
Jul 26Calculating The Intrinsic Value Of Wockhardt Limited (NSE:WOCKPHARMA)
May 18Calculating The Fair Value Of Wockhardt Limited (NSE:WOCKPHARMA)
Jan 26
What Did Wockhardt's (NSE:WOCKPHARMA) CEO Take Home Last Year?
Dec 01CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -₹3b |
| Mar 31 2024 | ₹21m | ₹20m | -₹5b |
| Dec 31 2023 | n/a | n/a | -₹5b |
| Sep 30 2023 | n/a | n/a | -₹5b |
| Jun 30 2023 | n/a | n/a | -₹6b |
| Mar 31 2023 | ₹24m | ₹23m | -₹6b |
| Dec 31 2022 | n/a | n/a | -₹6b |
| Sep 30 2022 | n/a | n/a | -₹5b |
| Jun 30 2022 | n/a | n/a | -₹3b |
| Mar 31 2022 | ₹24m | ₹17m | -₹2b |
| Dec 31 2021 | n/a | n/a | -₹787m |
| Sep 30 2021 | n/a | n/a | -₹567m |
| Jun 30 2021 | n/a | n/a | -₹867m |
| Mar 31 2021 | ₹24m | ₹24m | -₹3b |
| Dec 31 2020 | n/a | n/a | -₹2b |
| Sep 30 2020 | n/a | n/a | -₹3b |
| Jun 30 2020 | n/a | n/a | -₹3b |
| Mar 31 2020 | ₹24m | ₹24m | -₹2b |
| Dec 31 2019 | n/a | n/a | -₹1b |
| Sep 30 2019 | n/a | n/a | -₹2b |
| Jun 30 2019 | n/a | n/a | -₹2b |
| Mar 31 2019 | ₹24m | ₹24m | -₹3b |
| Dec 31 2018 | n/a | n/a | -₹3b |
| Sep 30 2018 | n/a | n/a | -₹3b |
| Jun 30 2018 | n/a | n/a | -₹3b |
| Mar 31 2018 | ₹24m | ₹19m | -₹6b |
Tazminat ve Piyasa: Murtaza's total compensation ($USD252.13K) is below average for companies of similar size in the Indian market ($USD471.41K).
Tazminat ve Kazançlar: Murtaza's compensation has been consistent with company performance over the past year.
CEO
Murtaza Khorakiwala (51 yo)
15.6yrs
Görev süresi
₹21,200,000
Tazminat
Dr. Murtaza Habil Khorakiwala serves as the Managing Director of Wockhardt Ltd. since April 2009 and has been its Executive Director since March 31, 2009. Dr. Khorakiwala serves as a Director of Khorakiwal...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder & Executive Chairman | 20.8yrs | ₹36.50m | 0.39% ₹ 746.7m | |
| MD & Executive Director | 15.6yrs | ₹21.20m | 0.19% ₹ 367.6m | |
| Executive Director | no data | ₹21.20m | 0.18% ₹ 351.0m | |
| Chief Financial Officer | 2.4yrs | Veri yok | Veri yok | |
| Chief Scientific Officer of New Drug Discovery | no data | ₹1.71m | Veri yok | |
| Senior Vice President of Legal | no data | Veri yok | Veri yok | |
| Chief Human Resource Officer | no data | Veri yok | Veri yok | |
| Senior Vice President of Business Development | no data | ₹1.61m | Veri yok | |
| Head of Global Regulatory Affairs | 10.8yrs | Veri yok | Veri yok | |
| President of Supply Chain | no data | Veri yok | Veri yok | |
| Managing Director of Wockhardt UK | no data | Veri yok | Veri yok | |
| President of Manufacturing | no data | Veri yok | Veri yok |
13.2yrs
Ortalama Görev Süresi
57yo
Ortalama Yaş
Deneyimli Yönetim: WOCKPHARMA's management team is seasoned and experienced (13.2 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder & Executive Chairman | 20.8yrs | ₹36.50m | 0.39% ₹ 746.7m | |
| MD & Executive Director | 15.7yrs | ₹21.20m | 0.19% ₹ 367.6m | |
| Executive Director | 15.6yrs | ₹21.20m | 0.18% ₹ 351.0m | |
| Non-Executive Independent Director | 4.3yrs | ₹1.10m | Veri yok | |
| Non-Executive & Independent Director | 8yrs | ₹1.70m | Veri yok | |
| Non-Executive Non- Independent Director | 7.1yrs | ₹300.00k | Veri yok | |
| Non Executive Independent Director | less than a year | Veri yok | Veri yok | |
| Independent Director | 1.3yrs | ₹1.00m | 0.000070% ₹ 134.3k |
7.5yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: WOCKPHARMA's board of directors are considered experienced (7.5 years average tenure).